Agenus is developing botensilimab and balstilimab for colorectal cancer, among other oncology indications. See why I continue ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Human life expectancy has doubled since the 1900s, mostly ...

Baird raised the price target for the Agenus Inc (NASDAQ:AGEN) stock to “an Outperform”. The rating was released on June 06, 2023, according to finviz. We previously noted in another research note ...

At 12 years of age, just 4.4% of high-risk kids given early introduction of peanut allergens from infancy to age 5 years ...

The stock is trading -70.99 percent below its 52-week high and 29.17 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a ...

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may ...

After hours: May 30 at 7:39 PM EDT Loading Chart for AGEN ...

Disclosures: Long cited honoraria from Bristol Myers Squibb and Pierre Fabre, and consulting or advisory roles with Agenus, ...

Trailing total returns as of 5/23/2024, which may include dividends or other distributions. Benchmark is S&P 500 ...

Disclosures: Long cited honoraria from Bristol Myers Squibb and Pierre Fabre, and consulting or advisory roles with Agenus, ...